67 / 150
Consideraciones prácticas sobre opioides. Efectos adversos
>
67
BIBLIOGRAFÍA
1. Rauck RL. Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist meth-
ylnaltrexone. Drugs. 2013;73:1297-306.
2. Clemens KE, Mikus G. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel
dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain. Expert
Opin Pharmacother. 2010;11:297-310.
3. Leppert W, Woron J. The role of naloxegol in the management of opioid-induced bowel dysfunction. Therap
Adv Gastroenterol 2016;9:736-46.
4. Larkin PJ, Sykes NP, Centeno C, et al. The management of constipation in palliative care: clinical practice rec-
ommendations. Palliat Med. 2008;22:796-807.
5. Sanmartín Moreira J. Guías clínicas de cuidados paliativos. Madrid: Arán Ediciones SL; 2007.
6. Bush SH, Bruera E. The Assessment and Management of Delirium in Cancer Patients. The Oncologist.
2009;14:1039-49.
7. Mercadante S, Porzio G, Gebbia V. New opioids. J Clin Oncol. 2014;32:1671-6.
8. Rodríguez D, Urrutia G, Escobar Y, et al. Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Break-
through Pain in Cancer Patients: A Systematic Review. J Pain Palliat Care Pharmacother. 2015;29:228-46.
9. Cahill K, Shehab RM, Hassan A, et al. Addiction to transmucosal fentanyl: Is it a cause for concern in cancer
pain management? Palliat Med. 2015;29:861-2.